

34th Annual Meeting of the European Association for the Study of Diabetes

Barcelona, Spain, September 1998

Abstracts

Index of Oral Presentations

OP 1	Indices of Glucose-Intolerance	A 3
OP 2	Therapeutic Aspects of Diabetic Nephropathy	A 4
OP 3	Experimental and Clinical Islet Transplantation	A 6
OP 4	Diabetes and Pregnancy-Clinical Aspects	A 7
OP 5	T-Cells in Type 1 Diabetes	A 9
OP 6	Defect Insulin Signalling Yields Insulin Resistance	A 10
OP 7	Antigens and Antibodies in Type 1 Diabetes	A 12
OP 8	Ion Channel Activity in β -Cells	A 13
OP 9	Exercise	A 15
OP 10	Lipids and Late Complications	A 16
OP 11	Retinopathy	A 18
OP 12	GLP	A 19
OP 13	Epidemiology of Type 1 Diabetes	A 21
OP 14	Islet Metabolism and Insulin Release	A 22
OP 15	Cellular Mechanisms of Vascular Dysfunction	A 24
OP 16	Lipids and Insulin Resistance	A 25
OP 17	Glycation	A 27
OP 18	Immunology and Diabetic Pregnancy	A 28
OP 19	Cardiovascular Disease, Risk Factors, Prediction and Genetics	A 30
OP 20	Genetics of Type 2 Diabetes	A 32
OP 21	Oxygen Radicals Cause Insulin Resistance	A 34
OP 22	Regulation of Insulin Exocytosis	A 36
OP 23	Pathophysiology of Diabetic Nephropathy	A 38
OP 24	Education, Outcome, Health Care Costs	A 40
OP 25	Myocardial Infarction in Diabetes	A 42
OP 26	Early Type 2 Diabetes	A 43
OP 27	Altered Intra Uterine Development and Insulin	A 44
OP 28	Devices	A 45
OP 29	Nutrition and Diet Therapy	A 46
OP 30	Transcriptional Control in β -Cells	A 47
OP 31	New Forms of Insulin Therapy	A 48
OP 32	Neuropathy	A 50
OP 33	Insulin Signal Transduction	A 52
OP 34	Nitric Oxide Vascular Reactivity	A 54
OP 35	Susceptibility and Resistance to β -Cell Damage	A 56
OP 36	Diabetic Embryopathy-Clinical and Experimental Advances	A 58
OP 37	New Therapies for Type 2 Diabetes	A 60
OP 38	Animal Models of Type 1 Diabetes	A 62
OP 39	Leptin in Obesity and Pregnancy	A 64
OP 40	Development and Regeneration of β -Cells	A 66
OP 41	Hypoglycaemia	A 68
OP 42	Epidemiology of Type 2 Diabetes	A 70
OP 43	Genetics of Type 1 Diabetes	A 72
OP 44	Risk Factors of the Diabetic Foot	A 73
OP 45	Quality of Life	A 74
OP 46	PKC-Activation and Vascular Function	A 75
OP 47	Patterns of Insulin Secretion from β -Cells	A 76
OP 48	Alterations in Glucose Metabolism	A 77

Index of Poster Presentations

PS 1	Genetics of Type 1 Diabetes	A 78
PS 2	Epidemiology of Type 1 Diabetes	A 82
PS 3	Prediction and Prevention of Type 1 Diabetes	A 86
PS 4	Environmental Factors	A 91
PS 5	Clinical Immunology	A 92
PS 6	Experimental Immunology	A 100
PS 7	Genetics of Type 2 Diabetes	A 104
PS 8	Epidemiology of Type 2 Diabetes	A 115
PS 9	Prediction and Prevention of Type 2 Diabetes	A 125
PS 10	β -Cell Development, Replication and Insulin Gene Expression	A 128

PS 11	Signal Transduction in β -Cells	A 133
PS 12	Ion Channels and Exocytosis	A 138
PS 13	Modulation of Insulin Secretion	A 150
PS 14	Cytokines and β -Cell Degeneration	A 154
PS 15	Islet and Pancreas Transplantation	A 163
PS 16	Amylin	A 166
PS 17	LADA	A 170
PS 18	Insulin Action: Signal Transduction and Insulin Resistance	A 171
PS 19	Insulin Action: Cardiovascular Effects	A 174
PS 20	Hormonal Action (Other)	A 176
PS 21	Hormone Receptors	A 179
PS 22	Glucose Transport	A 181
PS 23	Gastro-Entero-Pancreatic Factors	A 182
PS 24	Insulin Resistance: Tissue and Cellular Level	A 185
PS 25	Insulin Resistance: Intracellular	A 188
PS 26	Insulin Resistance: Cardiovascular	A 191
PS 27	Insulin Resistance: Whole Body	A 194
PS 28	Insulin Sensitivity: Methods	A 199
PS 29	Carbohydrate Metabolism	A 200
PS 30	Carbohydrate Metabolism: Hepatic Glucose Production	A 202
PS 31	Protein Metabolism	A 204
PS 32	Lipids I	A 205
PS 33	Lipoproteins	A 207
PS 34	Free Fatty Acids	A 209
PS 35	Obesity	A 212
PS 36	Treatment of Obesity	A 214
PS 37	Animal Models of Obesity	A 215
PS 38	Obesity and TNF α	A 217
PS 39	Leptin	A 218
PS 40	Clinical Diabetes	A 222
PS 41	Devices	A 226
PS 42	Pharmacological Agents	A 230
PS 43	Hypoglycaemia	A 240
PS 44	Insulin Therapy I	A 242
PS 45	Insulin Therapy II	A 247
PS 46	Diabetes Education – Health Care Delivery	A 250
PS 47	Psychology	A 255
PS 48	Clinical Pregnancy	A 256
PS 49	Experimental Pregnancy	A 261
PS 50	Exercise	A 263
PS 51	Nutrition and Diet Therapy	A 265
PS 52	Gastrointestinal Autonomic Neuropathy	A 267
PS 53	Neuropathy	A 270
PS 54	Diabetic Foot	A 275
PS 55	Retinopathy	A 280
PS 56	Treatment of Diabetic Nephropathy	A 284
PS 57	Clinical Nephropathy	A 285
PS 58	Genetics of Diabetic Nephropathy	A 293
PS 59	Pathogenesis of Diabetic Nephropathy	A 297
PS 60	Glycation	A 301
PS 61	Autonomic Neuropathy	A 303
PS 62	Endothelium and Vasomotion	A 309
PS 63	Endothelium in Vitro Studies	A 316
PS 64	Markers of Endothelial Damage	A 318
PS 65	Adhesion Molecules and Vascular Complications	A 320
PS 66	Oxidative Stress and Complications	A 321
PS 67	Bone Density	A 325
PS 68	Pathogenic Mechanisms of Complications	A 326
PS 69	Platelets, Coagulation, Rheology	A 328
PS 70	Atherosclerosis	A 333
PS 71	Homocysteine and Cardiovascular Disease	A 336
PS 72	Hypertension	A 338
PS 73	Coronary Heart Disease	A 342
PS 74	Lipids II	A 346
PS 75	Cardiovascular Risk Factors and Mortality	A 350

572

TIME RELATIONSHIP BETWEEN RISES IN REDUCED PYRIDINE NUCLEOTIDES AND INSULIN RELEASE

P. Lindström. Department of Histology and Cell Biology, Umeå University, Sweden

Abnormalities in first phase insulin release is an early indicator of faulty islet function in both Type I and Type II diabetes. To evaluate possible coupling of events for the initiation of insulin release, I have dissected temporal relationships of components of rat pancreatic islet stimulus-secretion coupling. Isolated rat pancreatic islets were perfused under a microscope equipped for microfluorimetry. Insulin release, NAD(P)H/NAD(P)⁺ ratios, and cytoplasmic calcium were studied in parallel. The rise in insulin release started later in experiments with mannose (60-75 s, $p < 0.05$ Mann-Whitney u test) when compared with glucose. Insulin release started earlier in overnight cultured islets stimulated with 20 mmol/l glucose (60 s, $P < 0.05$) or 3 mmol/l glucose + 17 mmol/l mannose (75-90 s, $P < 0.05$) when compared with freshly prepared islets. The protein kinase C activator 100 nmol/l phorbol-12-myristate-13-acetate shortened the lag time (60-75 s, $P < 0.01$). There was no difference between 12, 20, or 30 mmol/l glucose with regard to timing of onset of insulin release or rise in NAD(P)H fluorescence. The timing of rise in NAD(P)H was the same in experiments with mannose when compared with equimolar concentrations of glucose but the maximum effect of mannose was lower than that of glucose at all concentrations tested (up to 30 mmol/l). After 4 days' culture the rise in NAD(P)H fluorescence started slightly earlier (15 s, $P < 0.01$) than in freshly prepared islets. Increasing mitochondrial metabolism by 20 mmol/l ketoisocaproate induced an earlier rise in NAD(P)H fluorescence and insulin secretion when compared with stimulatory glucose. The time of rise in cytoplasmic calcium was the same for glucose and mannose. Conclusion: It is probably not the time of onset of increased hexose metabolic flux or differences in the initial amount of glycolytic signal(s) for exocytosis that govern the timing of onset of exocytosis. Instead, mitochondrial metabolism (probably ATP production), degree of protein phosphorylation at late steps in the exocytotic process, and kinetic properties of the rate of generating cell messages may be important.

574

A TOXIN-RESISTANT SNAP-25 FOR STUDYING THE ROLE OF SNAP-25 IN REGULATED INSULIN SECRETION

C. Gonelle-Gispert, P. A. Halban and K. Sadoul. Laboratoire Louis Jeantet, CMU, 1, rue Michel-Servet, 1211 Geneva 4, Switzerland

The tSNARE SNAP-25 is expressed in pancreatic B-cells and its cleavage by botulinum neurotoxin E (BoNT/E) abolishes stimulated secretion of insulin. Using RT-PCR we have detected both SNAP-25 isoforms a and b in primary pancreatic B-cells as well as in an insulin secreting cell line. For further studies on the role of SNAP-25 and its isoforms in insulin secretion, we wished to generate a SNAP-25 mutant resistant to cleavage by BoNT/E. When insulin secreting cells are treated with BoNT/E the toxin inactivates endogenous SNAP-25 thereby inhibiting stimulated insulin secretion. If the mutant SNAP-25 is expressed it will not be inactivated by toxin and its ability to restore insulin secretion can thus be tested. To this end we have generated and characterised a SNAP-25 molecule in which the sequence around the BoNT/E cleavage site (R176QIDRIM¹⁸²) has been changed to P176QIKRIT¹⁸². This is the sequence of the equivalent region of human SNAP-23 (P187-T¹⁹⁴) which has been shown to be resistant to BoNT/E. The mutant SNAP-25 was resistant to BoNT/E in vitro even after treatment with 50 nM toxin for 3h at 37°C, whereas half maximal cleavage of wild type SNAP-25 occurred after only 10 min with a toxin concentration of 10 nM. Mutant SNAP-25 was also toxin resistant in vivo when expressed (transient transfection) in toxin treated HIT cells in which endogenous SNAP-25 is cleaved. In such cells, mutant but not native SNAP-25b fully restored stimulated insulin secretion. In conclusion the SNAP-25 mutant has been shown to be completely resistant against toxin cleavage both in vitro and in vivo and to be functionally active in regulated insulin secretion. It will now be possible to determine whether the two isoforms can reconstitute regulated insulin release to a similar extent and, by introducing additional mutations in the toxin-resistant form, screen SNAP-25 domains for their functional importance in the exocytotic process.

573

THEORETICAL STUDY OF THE ROLE OF Na/Ca EXCHANGE IN THE REGULATION OF THE β -CELL ELECTRICAL ACTIVITY.

D. Gall¹, I. Susa², A. Herchuelz¹ and K. Bokvist³. ¹Lab. de Pharmacodynamie, ²Service de Chimie Physique, Université Libre de Bruxelles, Brussels, Belgium and ³Islet Cell Physiology, Novo Nordisk A/S, Copenhagen, Denmark.

Glucose-stimulated insulin secretion from pancreatic β cells is associated with the generation of electrical activity which consists in groups of action potentials superimposed on a plateau potential (bursts) interceded by silent more repolarized intervals. The burst duration is influenced by glucose concentration but the mechanisms involved remain the subject of much debate. The role of a Na/Ca exchange current in the regulation of the electrical activity of the mouse pancreatic β cell was investigated by combining the patch-clamp technique and mathematical modeling. We have recorded electrical activity from freshly isolated islets in the presence of 11 mM glucose before, during and after reducing extracellular Na⁺ concentration from 140 mM to 30 mM. This partial removal of extracellular Na⁺ results in a transient shortening of the plateau phase (during which action potentials are generated) and a slight (5 mV) hyperpolarization. Moreover, we have extended existing mathematical models of the pancreatic β cell to include the Na/Ca exchange current. Our numerical simulations of β -cell electrical activity reproduce the observed effects of Na⁺-removal. Furthermore, the model predicts that the activity of the exchanger is influenced by glucose-induced changes in the cytoplasmic Na⁺-concentration and that this could contribute to the effects of the secretagogue on β -cell electrical activity. We have also extended the model to a cluster of heterogeneous cells with gap-junctional coupling. Our results show that the exchanger plays a substantial role in the regulation of cytosolic free Ca²⁺ inside the islet.

575

HIERARCHY OF THE SIGNALS DRIVING PULSATILE INSULIN SECRETION

M.A. Ravier, P. Gilon and J.C. Henquin. Unité d'Endocrinologie et Métabolisme, University of Louvain, Brussels, Belgium.

Three types of signals occurring in β cells have been proposed to trigger the oscillations of insulin secretion induced by glucose: oscillations of metabolism, cytoplasmic [Ca²⁺]_i and protein kinase activity. This study was an attempt to establish the hierarchy between these three mechanisms. We followed the standard procedure of repetitive and sustained depolarizations of mouse islets with high [K]_o in the presence of diazoxide. In a medium containing 10 mM glucose, repetitive increases of [K]_o induced rises in [Ca²⁺]_i and pulses of insulin secretion. Continuous stimulation of PKA by dibutyryl cAMP (or forskolin) or PKC by a phorbol ester (PMA) did not dissociate the [Ca²⁺]_i and insulin responses from the [K]_o rises. However, the amplitude of the insulin pulses was consistently increased, while that of the Ca²⁺ pulses was either increased (PKA activation) or decreased (PKC activation). Receptor-mediated (acetylcholine + GLP-1) activation of both kinases increased the secretory response without altering the pacing imposed by the [Ca²⁺]_i oscillations. When [Ca²⁺]_i was steadily elevated by a sustained rise of [K]_o, insulin secretion was stable. Under these conditions, oscillations of metabolism imposed by periodic variations in the glucose concentration resulted in damped oscillations of secretion, much smaller than those occurring when [Ca²⁺]_i fluctuates and metabolism is stable. These results indicate that oscillations of [Ca²⁺]_i exert a greater control on the oscillations of insulin secretion than do Ca²⁺-independent variations of protein kinase activity or of other metabolic signals. That oscillations of metabolism entrain [Ca²⁺]_i oscillations remains possible.